Company news

Share this article:

Neose Technologies said it will reduce its staff by 35% in connection with the discontinuation of NE-180 (GlycoPEGylated erythropoietin), its experimental erythropoiesis-stimulating agent (ESA) for the treatment of anemia in patients with chronic kidney disease and cancer patients receiving chemotherapy. The company had intended to partner the Phase II compound to conduct a Phase III trial, but “safety concerns expressed in recent quarters about marketed ESAs have not only impacted the market potential for new ESAs, but also made it unlikely that a collaborative relationship could be formed for the future development of NE-180 in a reasonable time frame,” Neose CEO George Vergis, PhD, said in a statement. The decision allows Neose to forego $60-$80 million of incremental spending over the next two years. The firm said it will pay cash severance benefits of about $900,000, mostly in early 2008.

Share this article:
close

Next Article in Agency Gallery

Email Newsletters

More in Agency Gallery

Private View: Creating Compelling Experiences

Private View: Creating Compelling Experiences

In today's multi-channel environment, game-changing ideas blend creativity and sensory ideation to create a meaningful customer experience

Putting consumers at the center of your universe

Putting consumers at the center of your universe

The question should be: How do you simplify and identify the moments that mean the most to customers?

Did "pay-to-play" confab help Zohydro approval?

Did "pay-to-play" confab help Zohydro approval?

US senators Joe Manchin (D-WV) and David Vitter (R-LA) are asking whether a "pay-to-play" meeting between drug industry executives and FDA officials influenced the agency's approval of Zohydro